Regulation of biomarker analysis: what can Be translated in the clinic? [0.03%]
生物标志物分析的规范化：哪些可以转化为临床应用？
Marios A Diamantopoulos,Michaela A Boti,Triantafyllia Sarri et al.
Marios A Diamantopoulos et al.
Introduction: The introduction of biomarkers in precision medicine is heralding a new era of diagnostic power and personalized patient care. Biomarkers are critical tools for detecting various diseases, guiding treatment ...
The potency of cell-based assays to predict response to TNF inhibitor therapy [0.03%]
基于细胞的检测预测肿瘤坏死因子抑制剂疗效的能力
Noa Rose,Ari Polachek,Daniel Levinson et al.
Noa Rose et al.
Introduction: Tumor necrosis factor inhibitors (TNFi) have revolutionized rheumatic and inflammatory diseases therapy. Despite their efficacy, at least 30% of patients do not respond to TNFi therapy. There are five FDA-ap...
Genomic surveillance for viruses of Public health importance in Low-and-Middle-Income countries: opportunities and challenges [0.03%]
发展中国家公共卫生相关病毒的基因组监测：机遇与挑战
Ira Praharaj,Subhra Subhadra,Jyotsnamayee Sabat et al.
Ira Praharaj et al.
Valerio Gristina,Francesco Pepe,Francesca Rita Ogliari et al.
Valerio Gristina et al.
Introduction: Liquid biopsy (LB) has shifted the paradigm in cancer diagnosis and management, offering a minimally invasive and dynamic approach to understanding tumor biology. Advanced next-generation sequencing (NGS) te...
The diagnosis of Huntington's disease by different molecular tools: a systematic review [0.03%]
用于亨廷顿病诊断的不同分子工具的系统评价
Tiago César Gouvêa Moreira,Carmen Lucia Antão Paiva,Luciana Andrade Agostinho
Tiago César Gouvêa Moreira
Background: Huntington's disease (HD) is a neurodegenerative condition resulting from CAG trinucleotide expansion in the HTT. We reviewed various molecular tools for diagnosing HD and their respective validations and outl...
Circulating tumor DNA: a biomarker for oncology drug development in phase I clinical trials? [0.03%]
循环肿瘤DNA：一期临床试验中抗肿瘤药物研发的生物标志物吗？
Riccardo Asnaghi,Renato M Marsicano,Valeria Fuorivia et al.
Riccardo Asnaghi et al.
Introduction: Circulating tumor DNA (ctDNA) is a noninvasive and promising biomarker for cancer diagnosis, prognosis, and therapeutic monitoring, offering significant potential for real-time insights into tumor dynamics w...
Can multiplex molecular panels of microbial pathogens transform respiratory care in critically ill patients? [0.03%]
多重病原微生物分子检测对危重症患者呼吸系统感染诊治的影响及挑战
Julien Dessajan,Valentine Berti,Laurence Armand-Lefèvre et al.
Julien Dessajan et al.
Introduction: Diagnosing severe pneumonia accurately is often difficult because its clinical symptoms overlap with other respiratory illnesses. Treatment of severe lower respiratory tract infection (LRTI) should start ear...
Isothermal amplification for rapid and sensitive detection of hepatitis B virus: what we know so far? and way forward [0.03%]
等温扩增技术在乙型肝炎病毒快速检测中的应用及未来展望
Prerana Sharan,Ballamoole Krishna Kumar,Anoop Kumar et al.
Prerana Sharan et al.
Introduction: Despite vaccine availability, Hepatitis B Virus (HBV) remains a major global health threat, especially in areas with low vaccination coverage and poor healthcare. Around 250 million people are chronically in...
From barriers to solutions: an expert-based algorithm for cholangiocarcinoma and other biliary tract cancers testing in the Era of precision oncology [0.03%]
从障碍到解决方案：在精准肿瘤学时代的胆管癌和其他胆道癌症检测的专家算法
Albrecht Stenzinger,Nicola Normanno,Angela Lamarca et al.
Albrecht Stenzinger et al.
Introduction: Biliary tract cancer (BTC) comprises a group of aggressive malignancies with poor prognosis and limited therapeutic options. Next-generation sequencing (NGS) has advanced BTC management by identifying target...
Best practices in sample management and molecular profiling of cholangiocarcinoma: a practical guide [0.03%]
胆管癌样本管理和分子分型指导规范
Florian Castet,Maria Teresa Salcedo,Paolo Nuciforo et al.
Florian Castet et al.
Introduction: Cholangiocarcinoma (CCA) is an uncommon yet aggressive malignancy often diagnosed at advanced stages. Its management is challenged by significant molecular heterogeneity and limited treatment options. Advanc...